Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study.

Authors

Hirva Mamdani

Karmanos Cancer Institute, Detroit, MI

Hirva Mamdani , Bryan J. Schneider , Pashtoon Murtaza Kasi , Laith I. Abushahin , Thomas J. Birdas , Kenneth Kesler , Heather Burney , Susan Perkins , Shadia Ibrahim Jalal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consortium study.

First Author: Hirva Mamdani

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.

First Author: Hirva Mamdani

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study.

First Author: Hirva Mamdani

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

A phase II study of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-ESO14-012 study.

First Author: Hirva Mansurali Mamdani